As artificial intelligence reshapes the future of genomic medicine, WhiteLab Genomics is positioning itself at t...
Artificial intelligence is rapidly transforming biologics discovery, but the industry's focus is shifting from generatin...
Despite decades of advances in oncology, many solid tumours remain difficult to treat effectively without exposing patie...
As advanced therapeutics move from scientific promise to commercial reality, the industry's focus is shifting be...
The RNA revolution is entering a new chapter. While mRNA transformed the industry's perception of nucleic acid therapeut...
Cancer drug discovery is entering a more disciplined era. Investors, partners, and clinicians are increasingly focused o...
Cancer immunotherapy is entering a new phase—one that extends beyond targeting individual tumour cells and towards...
After several years of volatility, biotechnology financing has returned—but under very different rules. Investors ...
As biotechnology enters an increasingly data-driven era, organisations are rethinking how discovery, clinical developmen...
As biologics and cell and gene therapies continue to advance, manufacturing infrastructure is emerging as a critical det...
As cell and gene therapies move from clinical promise to commercial reality, the industry is increasingly recognising th...
Cell and gene therapies have transformed the treatment landscape for complex diseases, yet scaling these innovations bey...
As biotechnology enters a new phase of disciplined investment and precision-driven innovation, leaders who can bridge sc...
As biologics become increasingly sophisticated and development timelines continue to shrink, the role of Contrac...
At BIO International Convention 2026 in San Diego, BioSpectrum Asia spoke with Dr. Christoffer Norn, Co-founder and CEO ...
As life sciences laboratories embrace automation, digitalisation, and increasingly complex research workflows, technolog...
As cell and gene therapies advance toward commercial reality, the industry's focus is rapidly shifting beyond manufactur...
As biologics manufacturing continues to evolve, Asia Pacific is emerging as a key region for innovation in process inten...
Cell and gene therapy developers continue to face mounting pressure to improve manufacturing efficiency while maintainin...
Regenerative medicine is steadily redefining the future of cardiovascular care, with cell based therapies moving beyond ...
Cell and gene therapies have demonstrated remarkable clinical potential, but translating scientific breakthroughs into w...
As cell and gene therapies advance toward broader commercial adoption, the industry faces mounting pre...
As cell and gene therapies transition from clinical development to commercial reality, the industry's attention is incre...
As Asia’s biologics ecosystem continues to scale rapidly across monoclonal antibodies, biosimilars, and ad...
As biologics pipelines grow more complex and timelines tighten, early stage process decisions are becoming criti...
